BMI and TLC Influences Doxorubicin/Epirubicin Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer

Sasongko Hadi Priyono, Oscar Tri Joko Putra, Alfi Yasmina, Hery Poerwosusanta, Eka Yudha Rahman, Ika Kustiyah Oktaviyanti


Anthracycline-based neoadjuvant chemotherapy is the recommended therapy for locally advanced breast cancer (LABC) patients. Unfortunately, no study has reported the relationship between body mass index (BMI), total lymphocyte count (TLC), and responses to this type of chemotherapy. This study aimed to determine the relationship between BMI, TLC, and response to doxorubicin/epirubicin neoadjuvant chemotherapy in LABC patients. A retrospective cohort design was applied to medical records of LABC patients undergoing neoadjuvant chemotherapy at Ulin General Hospital Banjarmasin, Indonesia, from July to December 2021. BMI and TLC data were assessed based on the values before chemotherapy, while the chemotherapy response was measured using the RECIST 1.1 criteria after 3 cycles. Multinomial logistic regression test with 95% confidence level was used to analyze these data. The results showed that as many as 71% of patients experienced a Partial Response (PR), while 5% and 23% of the patients demonstrated Stable Disease (SD) and Progressive Disease (PD), respectively. Each increase in BMI of 1 kg/m2 was significantly associated with an increase in the occurrence of PR and PD by 1.26 times and 1.29 times, respectively, when compared to the occurrence of PD. Meanwhile, an increase in TLC of 100 cells/mm3 was associated with an increase in the occurrence of PR by 6.83 times and an increase in the occurrence of SD. of 6.94 when compared to the occurrence of PD. Therefore, there is a significant relationship between BMI, TLC, and response to anthracycline-based neoadjuvant chemotherapy in LABC patients


anthracyclines, body mass index, locally advanced breast cancer, neoadjuvant chemotherapy, total lymphocyte count

Full Text:



  1. DeSantis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69(6):452–67.
  2. Shumway DA, Sabolch A, Jagsi R. Breast Cancer. Med Radiol. 2020;1(1):1–43.
  3. Simos D, Clemons M, Ginsburg OM, Jacobs C. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8(1):33–8.
  4. Rustogi A, Budrukkar A, Dinshaw K, Jalali R. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther. 2005;1(1):21.
  5. Pathak M, Dwivedi SN, Deo SVS, Thakur B, Sreenivas V, Rath GK. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev. 2018;7(1):1–8.
  6. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940–9.
  7. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res. 2009;15(24):7693–700.
  8. Audrina GW, Purhadi P, Purwanto H. Faktor-Faktor yang mempengaruhi tingkat keberhasilan pemberian kemoterapi pada pasien penderita kanker payudara di RSUD Dr. Soetomo dengan menggunakan regresi logistik ordinal. J Sains dan Seni ITS. 2014;3(1):36–41.
  9. Xu J, Ni C, Ma C, Zhang L, Jing X, Li C, et al. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol. 2017;19(8):989–96.
  10. Lee OH, Min S-Y. Decrease of peripheral blood lymphocyte count predicts response to neoadjuvant chemotherapy in breast cancer patients. Korean J Clin Oncol. 2020;16(2):79–88.
  11. Khoshnevis N, Ahmadizar F, Alizadeh M, Akbari ME. Nutritional assessment of cancer patients in Tehran, Iran. Asian Pacific J Cancer Prev. 2012;13(4):1621–6.
  12. Rao R, Saha N, Mani V, Amritanshu R, Geetha R, Radheshyam N, et al. Pre-chemotherapy nutritional status and chemotherapy response: An observational study. Ann Oncol. 2017;28:v543.
  13. Sun Y, Bao W, Liu B, Caan BJ, Lane DS, Millen AE, et al. Changes in overall diet quality in relation to survival in postmenopausal women with breast cancer: Results from the Women’s Health Initiative. J Acad Nutr Diet. 2018;118(10):1855–63.
  14. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23(7):1370–8.
  15. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2015;107(12):djv275.
  16. Devoto G, Gallo F, Marchello C, Racchi O, Garbarini R, Bonassi S, et al. Prealbumin serum concentrations as a useful tool in the assessment of malnutrition in hospitalized patients. Clin Chem. 2006;52(12):2281–5.
  17. Santoso JT, Canada T, Latson B, Aaaadi K, Lucci III JA, Coleman RL. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet Gynecol. 2000;95(6):844–6.
  18. Wu Z, Zhang J, Cai Y, Deng R, Yang L, Li J, et al. Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. Medicine (Baltimore). 2018;97(38):1–5.
  19. Mandilaras V, Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, et al. Concurrent chemoradiotherapy for locally advanced breast cancer—time for a new paradigm?. Curr Oncol. 2015;22(1):25–32.
  20. Garg PK, Prakash G. Current definition of locally advanced breast cancer. Curr Oncol. 2015;22(5):409–10.
  21. Pradjatmo H, Pahlevi DP. Status gizi sebagai faktor prognosis penderita karsinoma endometrium. J Gizi Klin Indones. 2013;10(01):10–8.
  22. Conesa MAV, Garcia-Martinez E, Billalabeitia EG, Benito AC, Garcia TG, Garcia VV, et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. The Breast. 2012;21(4):468–74.
  23. Alpizar EJ, Gomez-Garcia EM, Rosas-Sanchez MA, Reyes-Barretero DY, Cruz-Ramos M. Nutritional Status and Chemoterapy associated toxicity in Patirnt with cervical cancer. Gaceta Mexicana de Oncologia. Gaceta Mexicana de Oncologia; 2017. 167–70.
  24. Rocha NP, Fortes RC. Total Lymphocyte Count and Serum Albumin as Predictors of Nutritional Risk in Surgical Patients. Brazilian Arch Dig Surg. 2015;28(3):193–6.


Article Metrics

Abstract view : 320 times
PDF - 290 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats